Quality-of-Life Assessment in Phase III Clinical Trials of Gemcitabine in Non-Small-Cell Lung Cancer

Author： Reynolds Jonathan K.  

Publisher： Adis International

ISSN： 1170-229X

Source： Drugs & Aging, Vol.25, Iss.11, 2008-01, pp. : 893-911

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

By Israel Valerie   Tagawa Scott   Snyder Terry   Jeffers Susan   Raghavan Derek  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 291-297

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors

By Danesi Romano   Altavilla Giuseppe   Giovannetti Elisa   Rosell Raffael  

Pharmacogenomics, Vol. 10, Iss. 1, 2009-01 ,pp. : 69-80

Future Medicine

Access to resources Recommend Favorite

The Role of Pemetrexed Combined with Gemcitabine for Non-Small-Cell Lung Cancer

By  

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 61-66

Bentham Science Publishers

Access to resources Recommend Favorite

Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer

By Sugiura Takahiko   Ariyoshi Yutaka   Negoro Shunichi   Nakamura Shinichiro   Ikegami Harumichi   Takada Minoru   Yana Takashi   Fukuoka Masahiro  

Investigational New Drugs, Vol. 23, Iss. 4, 2005-08 ,pp. : 331-337

Springer Publishing Company

Access to resources Recommend Favorite

Gemcitabine in non-small cell lung cancer

By Cappuzzo Federico   Crinò Lucio  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 6, 2002-06 ,pp. : 745-753

Informa Healthcare

Access to resources Recommend Favorite